62results about How to "Improve learning and memory function" patented technology

The tubiflorous desert cistanche preparation containing phenethyl alcohol glycoside contains echinacoside in 10-70 wt% and acteoside in 1-40 wt%. The preparation of the present invention may be applied as active component for preparing medicine treating and preventing senile dementia and for preparing medicine inhibiting platelet aggregation.

The invention relates to the technical field of medicines. The present invention provides application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia, and the nicotinamide mononucleotide can be used as an active pharmaceutical ingredient and a pharmaceutically acceptable supplementary material for preparation of medicine compositions. The nicotinamide mononucleotide compound itself is an endogenous protective substance, and the available data do not report the adverse reaction, so that the nicotinamide mononucleotide as a medicine or a health product is high in safety and wide in therapeutic window.

The invention relates to bamboo salt food tea and a production method thereof. The production method comprises the following steps of: drying materials such as lotus leaves, hemp fruits, pine needles, and mulberry leaves respectively; powdering the materials to obtain powder; adding bamboo salt into the powder to obtain a mixture; and performing high temperature sterilization on the mixture to prepare powder, tea bags, tablets or candies, or boiling the mixture in water and filtering the mixture to prepare aqueous beverage. Most people have moist, lustrous and firm facial skin, feel vigorous and difficultly feel tired in work, and the hair hardly becomes dry and yellow, whitens or drops off when the people drink the bamboo salt food tea for 1 to 3 months; and the bamboo salt food tea alsohas effects of lowering blood fat, blood pressure, and blood sugar, and has magical effects of curing stomach diseases, nourishing a stomach, and invigorating the stomach for the people who have all kinds of stomach diseases.

The invention relates to the technical field of medicine, in particular to Petasites tatewakianus Kitam. extract and novel sesquiterpene lactone compound bakkenolide VIIa separated from the Petasites tatewakianus Kitam. extract. The chemical structural formula of the bakkenolide VIIa is as shown in the specification. Animal experiments and in vitro experiments prove that the Petasites tatewakianus Kitam. extract or bakkenolide VIIa has the activities of preventing cerebral isochemia, myocardial isochemia, allergic rhinitis, tumor, dysmnesia and the like, thus the Petasites tatewakianus Kitam.extract or the bakkenolide VIIa can be used for preparing medicaments capable of preventing heart cerebrovascular diseases, allergic rhinitis, tumor, senile dementia, tristimania, histamine and/or leukocyte component-related diseases. The preparation method is simple, and the cost is low; and the invention provides a novel medicament source for preventing the heart cerebrovascular diseases, allergic rhinitis, tumor, senile dementia, tristimania, histamine and/or leukocyte component-related diseases.

The present invention is one kind of sobering-up and liver protecting bean product and its making process, and aims at increasing the nutritious components and health functions of bean product. The sobering-up and liver protecting bean product is produced with soybean 100 weight portions, kudzuvine flower 3-6 weight portions, kudzu vine root 5-13 weight portions, bitter orange seed 3-10 weight portions, finger citron 0.5-1 weight portion. The product of the present invention has no side effect and is suitable for eating regularly.

The invention discloses multiple-target effects of an isoflavone derivative and its application in improvement of learning and memory. Specifically, the invention discloses that a compound J39136 has the effects of: upregulating the expression of SIRT1 protein with damage repair and neuroprotective effects; inhibiting the activity of acetylcholinesterase and butyrylcholinesterase, and dose-dependently inhibiting the acetylcholinesterase activity of cells under a safe dose; protecting nerve cells, inhibiting abnormal expression of beta-APP, and reducing Abeta1-42 secretion; and regulating neuroinflammation. Animal experimental results prove that J39136 has low toxicity, can penetrate the blood-brain barrier, and can significantly improve scopolamine caused mouse dementia and strengthen learning and memory functions. Preclinical study results prompt that J39136 is expected to become the drug for prevention and/or treatment of learning and memory disorder and Alzheimer's disease.

The invention discloses a uses of procyanidins from lotus seedpod in preparation medicine for prevention of senile dementia and health care food. Specifically, relating to effects of procyanidins from lotus seedpod for the improvement of young mouse on learning and memory disorder caused by scopolamine and alcohol, also discussing its mechanism of action. Kunming mouse is taken as animal test in said invention, Y maze method adopted, testing the effect of procyanidins from lotus seedpod on learning and memory of the mouse, also testing brain tissue or content or activity of MDA, NO, NOS, SOD, AchE and MAO-B.

The invention relates to the application of hesperidin and/or naringin in the preparation of drugs for improving cognitive dysfunction.

The invention discloses a health-caring nutritional powder which mainly includes the following raw materials, by weight: 18-30 parts of black sesame, 18-24 parts of rhizoma polygonati, 6-12 parts of spirulina, 6-20 parts of seabuckthorn, and 9-15 parts of mulberries. A preparation method of the health-caring nutritional powder includes the following steps: 1) weighing the raw materials according to the weight part ratio: 18-30 parts of the black sesame, 18-24 parts of the rhizoma polygonati, 6-12 parts of the spirulina, 6-20 parts of the seabuckthorn, and 9-15 parts of the mulberries; 2) purifying black sesame, removing impurities, stir-frying the black sesame, and performing low-temperature crushing treatment to the stir-fried black sesame to obtain black sesame powder, wherein 100% of the black sesame powder should be capable of passing a sieve in 20 meshes; and 3) drying and pulverizing the rhizoma polygonati, the spirulina, the seabuckthorn and the mulberries and mixing the powders with the black sesame powder. The health-caring nutritional powder is low in fat content and is high in contents of protein, dietary fibers and vitamins, has excellent health-caring effect, can reinforce muscle and bone, improve immunity, improve eyesight and blacken hair, has balanced nutrition, has good taste and is suitable for people in all ages.

The invention discloses the application of forsythiaside in preparing medicine promoting nerve cell proliferation and protecting nerve cells; the application of forsythiaside in preparing medicine improving passive avoidance response and impaired spatial learning and memory and enhancing learning and memory; the application of forsythiaside in preparing medicine increasing the total protein content in cerebral cortex tissue; the application of forsythiaside in preparing medicine reducing the activity of acetylcholin esterase in cerebral cortex and hippocampus brain tissue; the application of forsythiaside in preparing medicine improving the activity of superoxide dismutase in cerebral cortex and hippocampus brain tissue, and reducing the malonaldehyde content and the monoamine oxidase activity in cerebral cortex and hippocampus brain tissue; the application of forsythiaside in preparing medicine reducing the content of inflammatory factor TNF-alpha and IL-6 in the brain tissue of cerebral cortex; and the application of forsythiaside in preparing medicine treating mild cognitive impairment, especially senile dementia.

The invention provides compound of brain protein hydrolyzate and maleic acid and a method for preparing the same and also provides a method for preparing dispersible tablets of the medicinal compound of brain protein hydrolyzate and maleic acid, belonging to the technical field of the medicament. The medicinal compound of brain protein hydrolyzate and maleic acid is the peptidergic neural nutritional medicament specially used for the brain and can act on the central nervous system in various ways to adjust and improve the neuronal differentiation. The medicinal compound of brain protein hydrolyzate and maleic acid can promote the synthesis of the brain protein through a blood-brain barrier, has the efficacy of preventing hypoxia, improving the brain energy metabolism and providing neurotransmitter, peptide hormones and coenzyme precursors and can be used for preparing the medicament for improving insomnia, headache, memory loss, irritability and other symptoms, promoting the rehabilitation of acute cerebral infarction and acute brain injury and treating brain dysfunction.

The invention belongs to the field of medical technology, and relates to an application of n-3 unsaturated fatty acid in preparation of a medicine for preventing and treating traumatic brain injury. The experimental results about the function of n-3PUFAs (polyunsaturated fatty acids) in resisting traumatic brain injury show that the n-3 unsaturated fatty acid can remarkably improve sense and motor functions of a mice after traumatic brain injury, slightly reduces the deletion of brain tissue after injury, inhibits the inflammatory response from excessive activation, promotes the repair of white matter damage, obviously reduces the degeneration and necrosis of nerve cells of CA3 area of hippocampus, and improves the study and memory functions. The n-3PUFAs has a definite neuroprotective effect in resisting brain injury, can be used for preparing nerve protective medicines, and can be used for preventing and treating acute or chronic injury caused by the traumatic brain injury.

The invention discloses a traditional Chinese medicine composition for treating alzheimer disease as well as a preparation method and an application thereof. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 2-6 parts of American ginseng, 5-15 parts of angelica sinensis, 7-15 parts of rhizoma corydalis, 4-12 parts of waternut herb, 4-12 parts of cremastra appendiculata, 2-6 parts of schisandra chinensis, 4-12 parts of stephania tetrandra, and 2-10 parts of polygala tenuifolia. The research shows that the traditional Chinese medicine composition can improve the learning and memory abilities of an AD mouse model and the visceral index of the immune organs, improve the permeability of the blood brain barrier of the AD mouse model, reduce the hippocampi APP, Abeta1-42, IL-1beta and IL-6 levels of the AD mouse, enhance the oxidation resistance of the hippocampi of the AD mouse, improve the hippocampi morphological structure of the AD mouse, and reduce the hippocampi RAGE and NF-kappaBp65 expressions of the AD mouse, and has no influences on the body weight of the AD mouse model. The traditional Chinese medicine composition, as well as the preparation method and the application thereof provide a novel technological means for the further research and development on the new traditional Chinese medicine for preventing and treating AD.

The invention discloses an application of luteolin in antagonizing the accumulation of beta-amyloid protein, improving cognitive memory and reducing senile plaques. The Alzheimer's disease (AD) is a neurodegenerative disease characterized by neurofibrillary tangles, beta-amyloid (A beta) plaque deposition, and cognitive decline, The accumulation of extracellular toxicity of A beta protein is considered as one of the main links in the pathogenesis of AD. The luteolin can significantly inhibit the accumulation of beta-amyloid protein 1-42 monomers to form fibers, inhibits the formation of a betasecondary structure, and improves the spatial memory learning ability of AD mice and significantly eliminates amyloid plaques in the brain tissue of APP/PS1 double transgenic AD model mice. The luteolin can be applied to the treatment of Alzheimer's disease and related drug development.

The invention relates to the field of biomedicine, in particular to a composition capable of improving water solubility of curcumin and application of the composition in preparation of a compound fortreating Alzheimer diseases (AD). In order to develop an efficient drug for resisting Alzheimer diseases, the invention provides the composition capable of improving the water solubility of curcumin.The composition comprises konjac polysaccharide, stevioside and hydroxyethyl cellulose, the solubility of curcumin in water can be modified effectively through the composition, the water solubility ofcurcumin can be improved, and the bioavailability of curcumin can be increased. At the same time, the compound for treating AD can be prepared through mixing of the composition, curcumin, alpha-GPC,polygonum multiflorum polysaccharide and tenuigenin, it is found through Morris water maze detecting experiments and determination experiments of the content of SOD, AchE and MDA that the purposes ofimprovement of the learning memory function and treatment of Alzheimer diseases can be achieved through improvement of the ability of free radical removal and promotion of release of acetyl choline, and the therapeutic effect is efficient and remarkable.

The invention discloses a medicinal composition with a neuroprotective effect and a preparing method thereof. Radix ginseng, radix astragali in parts by weight, herba scutellariae barbatae, ornithogalum saundersiae, rhizoma polygoni cuspidati, radix salviae miltiorrhizae, herba hedyotidis diffusae, radix curcumae, scolopendra and scorpion are utilized as raw materials. Water extract powder of the radix ginseng, the radix astragali and the scutellariae barbatae herb, alcohol extract powder of the ornithogalum saundersiae, the rhizoma polygoni cuspidati, the radix salviae miltiorrhizae and the herba hedyotidis diffusae, radix curcumae powder, scolopendra powder and scorpion powder are mixed to be manufactured into the medicinal composition. Pharmacological testing shows that the medicinal composition has the neuroprotective effect, is suitable for preventing and curing Alzheimer's disease and is obvious in curing effect.

The invention provides zinnia whitening foot bath powder and a preparation method thereof. Every 35 g of zinnia whitening foot bath powder is prepared from 20 g of traditional Chinese medicine mixed powder and 15 g of traditional Chinese medicine mixed residues. Every 20 g of traditional Chinese medicine mixed powder is prepared from zinnia, physalis alkekengi, chaulmoogratree seeds, rhizoma nardostachyos, ginkgos, kelp, fructus lycii, duckweed, Scutellaria indica and watermelon peel in the proportion of 10:(5-8):(4-7):(4-6):(3-5):(2-4):(2-3):(1-3):(2-3):(1-2). Every 15 g of traditional Chinese medicine mixed residues is obtained after the raw materials in 20 g of traditional Chinese medicine mixed powder are processed. The preparation method includes the steps that firstly, the raw materials are preprocessed; secondly, ultrasonic extraction is conducted; thirdly, concentration and drying are conducted; fourthly, smashing and sterilization are conducted. According to the zinnia whitening foot bath powder and the preparation method thereof, the preparation technology is simple and scientific, and the prepared foot bath powder is convenient to use, remarkable in treatment effect and good in whitening effect.

The present invention provides a novel aromatic amide as a Kv2.1 inhibitor and a preparation method, pharmaceutical composition, and use thereof. In particular, the present invention relates to an aromatic amide derivative shown in general formula I and a pharmaceutically acceptable salt thereof, a preparation method of the same, a composition comprising one or more such compounds, and a use of such compounds in preparing a drug for preventing and/or treating a disease related to Kv2.1.

The invention provides application of lupenone to preparation of a drug for prevention and/or treatment of senile dementia. Animal experiments indicate that lupenone has a high protection effect on a mouse with senile dementia caused by A beta 25-35 and a rat with senile dementia caused by D-galactose and AlCl3, the learning and memorizing functions can be remarkably improved, the activity of acetylcholin esterase (AchE) in brain tissue and the content of malonaldehyde (MDA) in blood can be obviously reduced, the content of choline acetyl transferase (ChAT) in the brain tissue and superoxide dismutase (SOD) and catalase (CAT) in the blood can be obviously increased, the abnormal phosphorylation level of Tau protein is lowered, and therefore lupenone can be used for preparing the drug for prevention and treatment of senile dementia.

The invention provides a traditional Chinese medicine composition for treating climacteric syndrome. The composition is prepared from the following components: 6.5-10.2 percent of angelica sinensis, 6.5-10.2 percent of radix paeoniae rubra, 6.5-10.2 percent of ligusticum wallichii, 6.5-10.2 percent of peach kernels, 5.4-8.0 percent of safflower carthamus, 5.4-8.0 percent of platycodon grandiflorum, 4.4-6.5 percent of radix achyranthis bidentatae, 4.4-6.5 percent of fructus aurantii, 5.4-8.0 percent of radix bupleuri, 4.4-6.5 percent of rhizoma cyperi, 4.4-6.5 percent of lindera aggregata, 5.4-8.0 percent of salvia miltiorrhiza, 5.4-8.0 percent of rhizoma corydalis, 4.4-6.5 percent of rhizoma cimicifugae and 4.4-6.5 percent of licorice roots. Medicine clinical testing results indicate that the traditional Chinese medicine composition has the effect of improving obesity signs of naturally aged climacteric female mouses, and can be used for preparing medicines for treating climacteric syndrome. The traditional Chinese medicine composition is reasonable in prescription, does not have adverse response or toxic or side effect, and has a great clinical application value. The preparation method is simple, and is suitable for industrial production.

The invention discloses a genistein derivative (5-hydroxy-7-O-ethylpiperidine isoflavone, DL0410-3, WS1102001). The genistein derivative has relatively strong inhibiting effects to the activities of acetylcholin esterase and butyrylcholine esterase and further has the efficacies of protecting nerves, improving oxidative stress and adjusting neuroinflammation. A prediction result of a compound anti-Alzheimer disease target prediction system shows that DL0410-3 is further capable of inhibiting the expression of APP and the activities of 5-HT4, GABA A and MAO B and activating alpha7nAChR. An animal experiment result shows that DL0410-3 is relatively low in toxicity and capable of penetrating through blood brain barriers; DL0410-3 is capable of obviously improving the dementia of mice caused due to scopolamine and enhancing the learning and memory functions under a safe dose; DL0410-3 is capable of obviously improving the dysfunction of learning and memory of mice caused due to galactose,adjusting neuroinflammation and alleviating oxidative stress injury; and DL0410-3 is capable of obviously improving dysfunction of learning and memory of APP/PS1 transgenic mice and obviously enhancing LTP of a Schaffer-CA1 region of extracorporeal hippocampal slices of the APP/PS1 transgenic mice.

The invention belongs to the biomedical field, and mainly relates to application of growth hormone releasing hormone receptor agonist MR-409 in preparation of drugs for preventing and treating ischemic brain infarction. The MR-409 is a novel GHRH receptor agonist, and preliminary researches prove that the MR-409 is capable of reducing pathological injury of refractory diseases such as diabetes mellitus and myocardial ischemia by increasing survival of multiple bone marrow stem cells in an ischemic focus. Researches in the invention prove that the MR-409 is capable of remarkably improving ischemic brain injury, survival rate and neurobehavioral manifestations of model mice with cerebral ischemia possibly through a mechanism of increasing proliferation, migration and survival of endogenous neural stem cells. The researches provide new strategies for treatment of the cerebral ischemia, have important clinic treatment significances and provide scientific and theoretical foundations for research and development of drugs utilizing regeneration of nerve cells as cerebral ischemia treating targets in future.